Both in Pharmaceuticals
Cytokinetics vs Arrowhead Research
Over the past year CYTK returned +4.7% and ARWR returned +51.9%; their daily moves had a correlation of 0.29.
CYTK +4.7% ARWR +51.9%Growth of $1, one year, split-adjusted
| Metric | CYTK | ARWR |
|---|---|---|
| Price | $62.86 | $60.15 |
| Market cap | $8.74B | $8.50B |
| Today | +1.34% | +0.97% |
| 1 month | +0.3% | −3.5% |
| 6 months | −18.5% | −19.7% |
| Year to date | −1.1% | −9.4% |
| 1 year | −1.1% | +41.9% |
| Revenue growth (YoY) | −57.1% | +171.0% |
| Gross margin | 90.5% | 100.0% |
| Net margin | −694.4% | −258.2% |
| P/E (TTM) | — | — |
| Price / sales | 129.1× | 12.7× |
| Net cash | $18.6M | $737.9M |
| Dividend yield | — | — |
| Volatility (60d) | 31.8% | 45.2% |
| Short % of float | 15.4% | 8.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).